La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Verrica Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Verrica Pharmaceuticals..

Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni, Catena delle Opzioni

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals Inc

NIVF

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

PTIXW

PBMWW

NIVFW

PTIX

SLGL

Kirby (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) has outperformed the market over the past 5 years by 2.3% on an annualized basis producing an average annual return of 16.94%. Currently, Kirby has a market capitalization of $5.94 billion. 
Buying $1000 In KEX: If an investor had bought $1000 of KEX stock 5 years ago, it would be worth $2,095.47 today based on a price of $104.48 for KEX at the time of writing.
<h3>Kirby's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746229512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 2.98% on an annualized basis producing an average annual return of 13.47%. Currently, Agnico Eagle Mines has a market capitalization of $55.88 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $362.54 today based on a price of $111.15 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746227716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

UBS analyst Andrew Spinola maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Neutral and lowers the price target from $11.5 to $11.

Price Target

Analyst Ratings

VIAV

UBS Maintains Neutral on Viavi Solutions, Lowers Price Target to $11

UBS analyst Taylor McGinnis maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and lowers the price target from $175 to $150.

TWLO

UBS Maintains Buy on Twilio, Lowers Price Target to $150

UBS analyst Karl Keirstead maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral and lowers the price target from $230 to $215.

TEAM

UBS Maintains Neutral on Atlassian, Lowers Price Target to $215

UBS analyst A.J. Rice maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Buy and lowers the price target from $90 to $88.

UBS Maintains Buy on Service Corp Intl, Lowers Price Target to $88

UBS analyst Seth Gilbert maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $32 to $28.

OTEX

UBS Maintains Neutral on Open Text, Lowers Price Target to $28

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) with a Neutral and lowers the price target from $15 to $13.5.

UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5

UBS analyst Peter Grom maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $175 to $170.

UBS Maintains Neutral on Hershey, Lowers Price Target to $170

UBS analyst Joseph Spak maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Neutral and lowers the price target from $51 to $50.

UBS Maintains Neutral on General Motors, Lowers Price Target to $50

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

FRSH

UBS Maintains Buy on Freshworks, Lowers Price Target to $19

Press Releases

Verrica Provides Business and Operational Update

Health Care

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Comments

Verrica Pharmaceuticals

Verrica Pharmaceuticals (VRCA) Opzioni

Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO